Combination of Basal Insulin and Tirzepatide (Mounjaro) for Patients with HbA1c ≈ 10 %

Therapeutic Recommendation

The American Diabetes Association recommends adding a dual GIP/GLP‑1 receptor agonist such as tirzepatide to basal insulin rather than intensifying insulin alone, because this combination yields superior glycemic control with less hypoglycemia and weight gain. 1
When titrating tirzepatide, increase to the next dose level (e.g., from 5 mg to 7.5 mg, 7.5 mg to 10 mg, or 10 mg to 12.5 mg weekly) according to the standard schedule; this is preferred over further basal‑insulin escalation for better HbA1c reduction, weight loss, and lower hypoglycemia risk. 1

Basal‑insulin titration:
A rise from 13 U twice daily to 16 U twice daily (total + 6 U) falls within the recommended titration range and is considered reasonable. 2
After each tirzepatide dose increase, reassess insulin needs because GLP‑1‑RA escalation typically lowers insulin requirements; failure to reduce insulin can precipitate hypoglycemia. 1

Over‑basalization threshold: total basal insulin > 0.5 U/kg/day (≈ 26 U twice daily for a 70‑kg adult, or ≈ 52 U total daily). 1
Clinical signs of over‑basalization include:
If basal insulin approaches the over‑basalization threshold without achieving glycemic targets, prioritize adding or intensifying tirzepatide rather than further basal‑insulin increases. 1
Daily monitoring: check fasting glucose each day during titration to guide additional insulin adjustments. 1
Insulin reduction after tirzepatide escalation: lower basal insulin by 10–20 % if hypoglycemia occurs, reflecting the typical decrease in insulin need with higher GLP‑1‑RA doses. 1
Hypoglycemia risk: remains low with the insulin + tirzepatide regimen compared with insulin intensification alone. 1

Combination therapy is expected to lower HbA1c by 2–3 % (e.g., from 10.3 % to ≈ 7–8 %) within 3–6 months. 2

Do not continue basal‑insulin escalation beyond 0.5 U/kg/day without first maximizing tirzepatide dose; doing so increases hypoglycemia risk and yields suboptimal control. 1
Do not postpone tirzepatide dose escalation while relying solely on insulin intensification, as this forfeits the opportunity for superior glycemic control and weight loss. 1
Do not overlook the need to reduce insulin when tirzepatide is up‑titrated; neglecting this can raise hypoglycemia risk. 1